Sign in to view content

How Do I Decide to Treat Patients with Geographic Atrophy?

Glenn J. Jaffe, MD

Video
Published 2024

Related

Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2020
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2023

Category: Geographic Atrophy

See more